RSS-Feed abonnieren
DOI: 10.1055/s-0028-1109338
© Georg Thieme Verlag KG Stuttgart · New York
Kombination von Antidepressiva – eine sinnvolle Behandlungsstrategie bei therapieresistenten Depressionen?
Combining Antidepressants: a Useful Strategy for Therapy Resistant Depression?Publikationsverlauf
Publikationsdatum:
04. Mai 2009 (online)

Zusammenfassung
Die folgende Arbeit fasst Nutzen und Risiken der bisher bekannten Kombinationsbehandlungen mit Antidepressiva bei therapieresistenten Depressionen zusammen. Die Literaturrecherche erfolgte mittels einer Medline-Datenbank-Recherche der Jahrgänge 1990 – 2006. Kombinationstherapien zweier Antidepressiva werden im klinischen Alltag sehr häufig durchgeführt. Sinnvolle Antidepressivakombinationen nutzen den Vorteil komplementärer Wirkmechanismen, um einen synergistischen Nutzen zu erzielen. Vorteile einer Kombinationstherapie bestehen in der Fortführung einer partiellen Response auf eine Monotherapie und dem gleichzeitig damit verbundenen Vermeiden der Gefahr einer Verschlechterung depressiver Symptome durch Absetzen des partiell wirksamen Antidepressivums. Nachteile dieser Strategie bestehen in dem Risiko von Arzneimittelwechselwirkungen, einer möglichen Potenzierung von unerwünschten Arzneimittelwirkungen und höheren Behandlungskosten. Obwohl Kombinationsstrategien in der klinischen Praxis oft angewandt werden, gibt es nur wenig kontrollierte Studien, um ihren Nutzen und ihre Wirksamkeit zu belegen (Evidenzlevel C, dies trifft auf alle Kombinationstherapien zu). Wichtig erscheint darauf hinzuweisen, dass die Zugabe eines SSRI zu einem Trizyklikum einen erhöhten Blutspiegel und eine verzögerte Metabolisierung des Trizyklikums herbeiführen kann, was eventuell ein erhöhtes Toxizitätsrisiko der trizyklischen Medikation nach sich führt. Die Kombination eines irreversiblen MAO-Hemmers mit Clomipramin, einem SSRI oder einem SSNRI sollte aufgrund eines möglichen Serotonin-Syndroms grundsätzlich vermieden werden.
Die detaillierte Kenntnis der dargestellten Kombinationsstrategien ermöglicht unter Umständen bessere Behandlungsergebnisse bei therapieresistenten Depressionen.
Abstract
Various pharmacological strategies have been developed to treat such refractory depression, of which combination therapies with antidepressants are one of the most important. This article reviews both benefits and risks of all known antidepressant combination strategies. The relevant literature was identified by means of a computerized MEDLINE research on the years 1990 – 2006 and scanning of review articles. The use of antidepressant combinations to overcome refractory depression is a common strategy in practice. Many antidepressants can be usefully combined especially if they engage separate mechanisms of action – like SSRIs with Reboxetine, Bupropion, Mirtazapine and Tricyclics – or on the other hand – Tricyclics with MAO-Inhibitiors. Combination strategies are effective treatment options, however they do have potential safety risks due to pharmacokinetic and pharmacodynamic interactions. Combinations including MAOIs can cause serotonin syndrome, and some SSRIs like Fluoxetine may elevate tricyclic plasma levels with the consequence of an increased risk of toxicity. The distinct knowledge of available antidepressant combination strategies may help to increase response – as well as remission rates in therapy resistant depression. However, further research is urgently needed to determine relative efficacy.
Schlüsselwörter
Antidepressiva - therapieresistente Depression - Kombinationen von Antidepressiva - Antidepressivanonresponse
Key words
antidepressants - therapy resistant depression - refractory depression - combination therapies with antidepressants
Literatur
- 1
Amsterdam J D, Hornig-Rohan M.
Treatment algorithms in treatment-resistant depression.
Psychiatr Clin North Am.
1996;
19
371-386
Reference Ris Wihthout Link
- 2
Dunner D L, Rush A J, Russell J M. et al .
Prospective long-term, multicenter study of the naturalistic outcomes of patients
with treatment-resistant depression.
J Clin Psychiatry.
2006;
67
688-695
Reference Ris Wihthout Link
- 3
Fawcett J.
Progress in treatment-resistant and treatment-refractory depression: we still have
a long way to go.
J Clin Psychiatry.
1994;
24
214-216
Reference Ris Wihthout Link
- 4
Nelson J C.
Managing treatment-resistant major depression.
J Clin Psychiatry.
2003;
64
5-12
Reference Ris Wihthout Link
- 5
Nierenberg A A, Amsterdam J D.
Treatment-resistant depression: definition and treatment approaches.
J Clin Psychiatry.
1990;
51 (Suppl 6)
39-47
Reference Ris Wihthout Link
- 6
Souery D, Amsterdam J, Montigny de C. et al .
Treatment resistant depression: methodological overview and operational criteria.
Eur Neuropsychopharmacol.
1999;
9
83-91
Reference Ris Wihthout Link
- 7
Thase M E, Rush A J.
When at first you don’t succeed: sequential strategies for antidepressant nonresponders.
J Clin Psychiatry.
1997;
58 (Suppl 13)
23-29
Reference Ris Wihthout Link
- 8 Burrows G D, Norman T R. Treatment-resistant unipolar depression. Lader M, Naber D Difficult Clinical Problems in Psychiatry London; Martin Dunitz Ltd 1999: 57-75
Reference Ris Wihthout Link
- 9
Guscott R, Grof P.
The clinical meaning of refractory depression: a review for the clinician.
Am J Psychiatry.
1991;
148
695-704
Reference Ris Wihthout Link
- 10 Rush A J. Aktueller Stand und Perspektiven der Forschung. Bauer M, Berghöfer A, Adli M Akute und therapieresistente Depressionen Heidelberg; Springer 2005: 3-19
Reference Ris Wihthout Link
- 11
Schmauß M, Meller I.
Die „therapieresistente” Depression – Ursachen und Behandlungsmöglichkeiten.
Psychiatr Prax.
1989;
16
101-108
Reference Ris Wihthout Link
- 12 Helmchen H. Gestuftes Vorgehen bei Resistenz gegen Antidepressiva-Therapie. Möller HJ Therapieresistenz unter Antidepressiva-Behandlung Heidelberg; Springer 1990: 237-250
Reference Ris Wihthout Link
- 13
Möller H J.
Therapieresistenz auf Antidepressiva: Risikofaktoren und Behandlungsmöglichkeiten.
Nervenarzt.
1991;
62
658-669
Reference Ris Wihthout Link
- 14
Möller H J.
Non-response to antidepressants: risk factors and therapeutic possibilities.
In Clin Psychopharmacol.
1994;
9 (Suppl 2)
17-23
Reference Ris Wihthout Link
- 15
Möller H J.
Therapieresistenz auf Antidepressiva.
Nervenarzt.
2004a;
75
499-517
Reference Ris Wihthout Link
- 16
Möller H J.
Medikamentöse Therapiestrategien bei therapieresistenter unipolarer Depression.
Psychopharmakotherapie.
2004b;
11
34-41
Reference Ris Wihthout Link
- 17
Sackheim H A.
The definition and meaning of treatment-resistant depression.
J Clin Psychiatry.
2001;
62 (Suppl 16)
10-17
Reference Ris Wihthout Link
- 18 Möller H J. Therapieresistenz unipolarer depressiver Erkrankungen: Häufigkeit, Prädiktoren, Risikofaktoren. Berghöfer A, Adli M Akute und therapieresistente Depressionen Heidelberg; Springer 2005: 21-37
Reference Ris Wihthout Link
- 19
Fava M, Davidson K G.
Definition and epidemiology of treatment-resistant depression.
Psychiatr Clin North Am.
1996;
19
179-200
Reference Ris Wihthout Link
- 20
Fava M.
Augmentation and combination strategies in treatment-resistant depression.
J Clin Psychiatry.
2001;
62 (Suppl 18)
4-11
Reference Ris Wihthout Link
- 21
Fredman S J, Fava M, Kienke A S. et al .
Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors
in major depression: a survey of current ”next-step” practices.
J Clin Psychiatry.
2000;
61
403-408
Reference Ris Wihthout Link
- 22
McIntyre R S, Muller A, Mancini D A. et al .
What to do if an initial antidepresant fails?.
Can Fam Physician.
2003;
49
449-457
Reference Ris Wihthout Link
- 23
Nelson J C.
Augmentation strategies with serotonin-noradrenergic combinations.
J Clin Psychiatry.
1998a;
59
65-68
Reference Ris Wihthout Link
- 24
Nelson J C.
Treatment of antidepressant nonresponders: augmentation or switch?.
J Clin Psychiatry.
1998b;
59 (Suppl 15)
35-41
Reference Ris Wihthout Link
- 25
Nelson J C.
Augmentation strategies in depression 2000.
J Clin Psychiatry.
2000;
61 (Suppl 2)
13-19
Reference Ris Wihthout Link
- 26
Nemeroff C B.
Augmentation strategies in patients with refractory depression.
Depress Anxiety.
1996;
4
169-181
Reference Ris Wihthout Link
- 27
Nierenberg A A, White K.
What next? A review of pharmacologic strategies for treatment resistant depression,
Psychopharmacol.
Bull.
1990;
26
429-460
Reference Ris Wihthout Link
- 28
Nolen W A, Haffmans J.
Treatment of resistant depression. Review on the efficacy of various biological treatments,
specifically in major depression resistant to cyclic antidepressants.
Intern Clin Psychopharmacol.
1989;
4
217-228
Reference Ris Wihthout Link
- 29
Pasternak M, Zimmerman M.
Switching versus augmentation: a prospective, naturalistic comparison in depressed
treatment resistant patients.
J Clin Psychiatry.
2001;
62
135-142
Reference Ris Wihthout Link
- 30
Trivedi M H, Kleiber B A.
Algorithm for the treatment of chronic depression.
J Clin Psychiatry.
2001a;
62 (Suppl 6)
22-29
Reference Ris Wihthout Link
- 31
Trivedi M H, Kleiber B A.
Using treatment algorithms for the effective management of treatment-resistant depression.
J Clin Psychiatry.
2001b;
62 (Suppl 18)
25-29
Reference Ris Wihthout Link
- 32
Trivedi M H.
Treatment-resistant depression: new therapies on the horizon.
Ann Clin Psychiatry.
2003;
15
59-70
Reference Ris Wihthout Link
- 33
Fava M, Rush A J.
Current status of augmentation and combination treatments for major depressive disorder:
a literature review and a proposal for a novel approach to improve practice.
Psychother Psychosom.
2006;
3
139-153
Reference Ris Wihthout Link
- 34
DeBattista C.
Augmentation and combination strategies for depression.
J Psychopharmacol.
2006;
20
11-18
Reference Ris Wihthout Link
- 35 Schmauß M. Kombinationstherapie nicht-selektiver Monoamin-Rückaufnahme-Inhibitoren mit MAO-Hemmern. Riederer P, Laux G, Pöldinger W Neuro-Psychopharmaka, Bd 3: Antidepressiva Phasenprophylaktika und Stimmungsstabilisierer Wien; Springer 2002: 551-557
Reference Ris Wihthout Link
- 36
Dodd S, Horgan D, Malhi G S. et al .
To combine or not to combine? A literature review of antidepressant combination therapy.
J Affect Disord.
2005;
89
1-11
Reference Ris Wihthout Link
- 37
Tanum L H.
Combination treatment with antidepressant in refractory depression.
Int Clin Psychopharmacoly.
1994;
9
37-40
Reference Ris Wihthout Link
- 38
De la Gandara J, Aguera L, Rojo J E. et al .
Use of antidepressant combinations: which, when and why? Results of a Spanish survey.
Acta Psychiatr Scand.
2005;
112 (Suppl. 428)
32-36
Reference Ris Wihthout Link
- 39
Frye M A, Ketter T A, Leverich G S. et al .
The increasing use of polypharmacotherapy for refractory mood disorders: 22 years
of study.
J Clin Psychiatry.
2000;
61
9-15
Reference Ris Wihthout Link
- 40
Schmauß M, Messer T.
Augmentationsstrategien bei Therapieresistenz auf Antidepressiva.
Psychiat Prax.
2007;
34
165-174
Reference Ris Wihthout Link
- 41
Murphy D L, Sunderland T, Cohen R M.
Monoamine oxidase-inhibiting antidepressants – a clinical update.
Psychiatr Clin North Am.
1984;
7
549-562
Reference Ris Wihthout Link
- 42
Schuckit M, Robins E, Feighner J.
Tricyclic antidepressants and monoamine oxidase inhibitors.
Arch Gen Psychiatry.
1971;
24
509-514
Reference Ris Wihthout Link
- 43 Cohen S N, Armstrong M F. Drug interactions: a handbook for clinical use. Baltimore; Williams & Wilkins 1974
Reference Ris Wihthout Link
- 44
Sjöqvist F.
Psychotropic drugs II: interaction between monoamine oxidase (MAO) inhibitors and
other substances.
Proc R Soc Med.
1965;
58
967-978
Reference Ris Wihthout Link
- 45
Ananth J, Luchins D A.
A review of combined tricyclic and MAOI therapy.
Compr Psychiatry.
1977;
18
121-134
Reference Ris Wihthout Link
- 46
Ponto L B, Perry P J, Liskow B I. et al .
Drug therapy reviews: tricyclic antidepressant and monoamine oxidase inhibitor combination
therapy.
Am J Hosp Pharm.
1977;
34
955-961
Reference Ris Wihthout Link
- 47
White K, Simpson G.
Combined MAOI-tricyclic antidepressant treatment. A reevaluation.
J Clin Psychopharmacol.
1981;
1
264-282
Reference Ris Wihthout Link
- 48
White K, Simpson G.
The combined use of MAOIs and tricyclics.
J Clin Psychiatry.
1984;
45
67-69
Reference Ris Wihthout Link
- 49 Marks J. Interaction involving drugs used in psychiatry. Marks J, Pare CMB The scientific basis of drug therapy in psychiatry Oxford; Pergamon 1965: 191-201
Reference Ris Wihthout Link
- 50
Davidson J.
Adding a tricyclic antidepressant to a monoamine oxidase inhibitor.
J Clin Psychopharmacol.
1982;
3
216
Reference Ris Wihthout Link
- 51
Lam R W, Wan D D, Cohen N L. et al .
Combining antidepressants for treatment-resistant depression. A review.
J Clin Psychiatry.
2002;
63
685-693
Reference Ris Wihthout Link
- 52
Berlanga C, Ortega-Soto H A.
A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic
combination.
J Affect Disord.
1995;
34
187-192
Reference Ris Wihthout Link
- 53
Feighner J P, Herbstein J, Damlouji N.
Combination MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.
J Clin Psychiatry.
1985;
46
206-209
Reference Ris Wihthout Link
- 54
Schmauß M, Kapfhammer H P, Meyr P. et al .
Combined MAO-inhibitor and tri(tetra)cyclic antidepressant treatment in therapy resistant
depression.
Prog Neuro Psychopharmacol Biol Psychiatry.
1988;
12
523-532
Reference Ris Wihthout Link
- 55
Davidson J, Mc L eod MN, Law-Yone B. et al .
A comparison of electroconvulsive therapy and combined phenelzine amitriptyline in
refractory depression.
Arch Gen Psychiatry.
1978;
35
639-642
Reference Ris Wihthout Link
- 56
Young J PR, Lader M H, Hughes W C.
Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment
in depressed outpatients.
Br Med J.
1979;
2
1315-1317
Reference Ris Wihthout Link
- 57
Razzani J, White K, White J. et al .
The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant
treatment.
Arch Gen Psychiatry.
1983;
40
657-661
Reference Ris Wihthout Link
- 58
White K, Pistole T A, Boyd J.
Combined monoamine oxidase inhibitor tricyclic antidepressant treatment. A pilot study.
Am J Psychiatry.
1980;
137
1422-1425
Reference Ris Wihthout Link
- 59
O’Brien S, McKeon P, O’Regan M.
The efficacy and tolerability of combined antidepressant treatment in different depressive
subgroups.
Br J Psychiatry.
1993;
163
363-368
Reference Ris Wihthout Link
- 60 Pande A C, Calarco M M, Grunhaus L J. Combined MAOI-TCA treatment in refractory depression. Amsterdam JD Advances in neuropsychiatry and psychopharmacology, vol 2: refractory depression New York; Raven Press 1991: 115-121
Reference Ris Wihthout Link
- 61
Goldberg R S, Thornton W E.
Combined tricyclic-MAOI therapy for refractory depression: a review, with guidelines
for appropriate usage.
J Clin Pharmacol.
1978;
18
143-147
Reference Ris Wihthout Link
- 62
Spiker D G, Pugh D D.
Combining tricyclic and monoamine oxidase inhibitor antidepressants.
Arch Gen Psychiatry.
1976;
33
828-830
Reference Ris Wihthout Link
- 63
Oefele v K, Grohmann R, Hippius H. et al .
Unerwünschte Arzneimittelwirkungen bei der Kombinationsbehandlung mit trizyklischen
Antidepressiva und Monoaminoxidase-Hemmern.
Nervenarzt.
1988;
59
118-123
Reference Ris Wihthout Link
- 64
Beaumont G.
Drug interactions with clomipramine (Anafranil).
J Int Med Res.
1973;
1
480-484
Reference Ris Wihthout Link
- 65
Marley E, Wozniak K M.
Clinical and experimental aspects of interactions between amine oxidase inhibitors
and amine reuptake inhibitors.
Psychol Med.
1983;
13
735-749
Reference Ris Wihthout Link
- 66
Amsterdam J D, Berwish N.
Treatment of refractory depression with combination reserpine and tricyclic antidepressant
therapy.
J Clin Psychopharmacology.
1992;
7
238-242
Reference Ris Wihthout Link
- 67
Hüttemann K, Nowe T, Köhrmann M. et al .
Maligne Hyperthermie und deren Differentialdiagnosen.
Fortschr Neurol Psychiat.
2009;
77
(im Druck)
Reference Ris Wihthout Link
- 68
Sternbach H.
Danger of MAOI therapy after fluoxetine withdrawal.
Lancet.
1988;
II
850-851
Reference Ris Wihthout Link
- 69
Feighner J P, Boyer W F, Tyler D L. et al .
Adverse consequences of fluoxetine-MAOI combination therapy, J.
Clin Psychiatry.
1990;
51
222-225
Reference Ris Wihthout Link
- 70
Beasley C M, Masica D N, Heiligenstein J H. et al .
Possible monoamine oxidase inhibitor serotonin uptake inhibitor interaction: Fluoxetine
clinical data and preclinical findings.
J Clin Psychopharmacol.
1993;
13
312-320
Reference Ris Wihthout Link
- 71
Hodgman M J, Martin T G, Krenzelok E P.
Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy.
Human and Exp Toxicology.
1997;
16
14-17
Reference Ris Wihthout Link
- 72
Boyer E W, Shannon Jr M.
The serotonin syndrome.
N Engl J Med.
2005;
352
1112-1120
Reference Ris Wihthout Link
- 73
Steinberg R, Jost C, Weess H G. et al .
Combination of tricyclic antidepressants with moclobemide or tranylcypromine – outcome
data in therapy resistant MD.
Neuropsychopharmacology.
1994;
10 (Suppl)
62
Reference Ris Wihthout Link
- 74
Koenig F, Wolfersdorf M.
Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants
to treat therapy-resistant depression.
Pharmacopsychiatry.
1997;
30
93-96
Reference Ris Wihthout Link
- 75
Koenig F, Wolfersdorf M, Loble M. et al .
Trimipramine and maprotiline plasma levels during combined treatment with moclobemide
in therapy-resistant depression.
Pharmacopsychiatry.
1997;
30
125-127
Reference Ris Wihthout Link
- 76
Bakish D, Hooper C L, West D L. et al .
Moclobemide and specific serotonin re-uptake inhibitor combination treatment of resistant
anxiety and depressive disorders.
Hum Psychopharmacol.
1995;
10
105-109
Reference Ris Wihthout Link
- 77
Joffe R T, Bakish D.
Combined SSRI-moclobemide treatment of psychiatric illness.
J Clin Psychiatry.
1994;
55
24-25
Reference Ris Wihthout Link
- 78
Ebert D, Albert R, May A. et al .
Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy.
Psychopharmacology.
1995;
119
342-344
Reference Ris Wihthout Link
- 79
Neuvonen P, Pohjola-Sintonen S, Tacke U. et al .
Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine
overdoses.
Lancet.
1993;
342
1419
Reference Ris Wihthout Link
- 80
Hawley C J, Quick S J, Ratnam S.
Safety and tolerability of combined treatment with moclobemide and SSRI: a systematic
study of 50 patients.
Int Clin Psychopharmacol.
1996;
11
187-191
Reference Ris Wihthout Link
- 81
Lejoyeux M, Adès J, Rouillon F.
Serotonin syndrome. Incidence, symptoms and treatment.
CNS Drugs.
1994;
2
132-143
Reference Ris Wihthout Link
- 82
Dams R, Benijts T H, Lambert W E. et al .
A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication.
J Anal Toxicol.
2001;
25
147-151
Reference Ris Wihthout Link
- 83
Volz H P, Gleiter C H, Möller H J.
Monoaminoxidasehemmer in der Psychiatrie.
Nervenarzt.
1996;
67
339-347
Reference Ris Wihthout Link
- 84
Bonnet U.
Moclobemide: therapeutic use and clinical studies.
CNS Drug Rev.
2003;
9
97-140
Reference Ris Wihthout Link
- 85
Weilburg J B, Rosenbaum J F, Biederman J. et al .
Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders:
a preliminary report.
J Clin Psychiatry.
1989;
50
447-449
Reference Ris Wihthout Link
- 86
Vaughan D A.
Interaction of fluoxetin with tricyclic antidepressants (letter).
Am J Psychiatry.
1988;
145
1478
Reference Ris Wihthout Link
- 87
Weilburg J B, Rosenbaum J F, Biedermann J. et al .
Tricyclic augmentation of fluoxetine.
Ann Clin Psychiatry.
1991;
3
209-213
Reference Ris Wihthout Link
- 88 Rosenthal J S, Kaswan M J, Hemlock C. et al .Fluoxetine enhancement of heterocyclic antidepressants. Amsterdam JD Advances in neuropsychiatry and psychopharmacology, vol 2: refractory depression New York; Raven Press 1991: 105-108
Reference Ris Wihthout Link
- 89
Levitt A J, Joffe R T, Kamil R. et al .
Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant
respond to the combination?.
J Clin Psychiatry.
1999;
60
613-616
Reference Ris Wihthout Link
- 90
Rothschild B S.
Fluoxetine-nortriptyline therapy of treatment resistant major depression in a geriatric
patient.
J Geriatric Psych Neurol.
1994;
7
137-138
Reference Ris Wihthout Link
- 91
Seth R, Jennings A L, Bindman J. et al .
Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant
depression.
Br J Psychiatry.
1992;
161
562-565
Reference Ris Wihthout Link
- 92
Zajecka J M, Jeffriess H, Fawcett J.
The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant
depression: a retrospective analysis.
J Clin Psychiatry.
1995;
56
338-343
Reference Ris Wihthout Link
- 93
Baron B M, Ogden A, Seigel B W. et al .
Rapid down regulation of β-adrenoreceptors by co-administration of desipramine and
fluoxetine.
Eur J Pharmacol.
1988;
154
125-134
Reference Ris Wihthout Link
- 94
Nelson J C, Mazure C M, Bowers M BJ. et al .
A preliminary, open study of the combination of fluoxetine and desipramine for rapid
treatment of major depression.
Arch Gen Psychiatry.
1991;
48
303-307
Reference Ris Wihthout Link
- 95
Fava M, Rosenbaum J F, Mc Grath P J. et al .
Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression:
A double blind controlled study.
Am J Psychiatry.
1994;
151
1372-1374
Reference Ris Wihthout Link
- 96
Fava M, Alpert J, Nierenberg A A. et al .
Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation
of fluoxetine in partial responders and nonresponders to fluoxetine.
J Clin Psychoharmacol.
2002;
22
379-387
Reference Ris Wihthout Link
- 97
Perlis R H, Iosifescu D V, Alpert J. et al .
Effect of medical comorbidity on response to fluoxetine augmentation or dose increase
in outpatients with treatment-resistant depression.
Psychosomatics.
2004;
45
224-229
Reference Ris Wihthout Link
- 98
Nelson J C, Mazure C M, Jatlow P I. et al .
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment
of depression: a double-blind, randomized study.
Biol Psychiatry.
2004;
55
296-300
Reference Ris Wihthout Link
- 99 Blecourt C V de, Gudde H. Surplus value of combining antidepressants in refractory depression. Second International
Conference on Refractory Depression. Abstract Amsterdam; 24.–26. Juni 1992
Reference Ris Wihthout Link
- 100
Lauritzen L, Clemmensen L, Klysner R. et al .
Combined treatment with imipramine and mianserine. A controlled pilot study.
Pharmacopsychiatry.
1992;
25
182-186
Reference Ris Wihthout Link
- 101 Klysner R, Geisler A. Rapid downregulation of cerebral β-adrenoreceptors by combined treatment with imipramine
and mianserin. Amsterdam JD Advances in neuropsychiatry and psychopharmacology, vol 2: refractory depression New York; Raven Press 1991: 109-113
Reference Ris Wihthout Link
- 102
Nierenberg A A, Cole J O, Glass L.
Possible trazodone potentation of fluoxetine: a case series.
J Clin Psychiatry.
1992;
53
83-85
Reference Ris Wihthout Link
- 103
Maes M, Vandoolaeghe E, Desnyder R.
Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in
major depression.
J Affect Disord.
1996;
41
201-210
Reference Ris Wihthout Link
- 104
Clark N A, Alexander B.
Increased rate of trazodone prescribing with bupropion and selective serotonin-reuptake
inhibitors versus tricyclic antidepressants.
Ann Pharmacother.
2000;
34
1007-1012
Reference Ris Wihthout Link
- 105
Dam J, Ryde L, Svejso J. et al .
Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo
in the acute treatment of major depression.
Pharmacopsychiatry.
1998;
31
48-54
Reference Ris Wihthout Link
- 106
Ferreri M, Lavergne F, Berlin I. et al .
Benefits from mianserin augmentation of fluoxetine in patients with major depression
non-responders to fluoxetine alone.
Acta Psychiatr Scand.
2001;
103
66-72
Reference Ris Wihthout Link
- 107
Maes M, Libbrecht I, Hunsel van F. et al .
Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized
major depressed patients, including those with treatment resistance.
J Clin Psychopharmacol.
1999;
19
177-182
Reference Ris Wihthout Link
- 108
Licht R W, Qvitzau S.
Treatment strategies in patients with major depression not responding to first-line
sertraline treatment: a randomised study of extended duration of treatment, dose increase
or mianserin augmentation.
Psychopharmacology.
2002;
161
143-151
Reference Ris Wihthout Link
- 109
Harkin A, Kelly J P, McNamara M. et al .
Activity and onset of action of reboxetine and effect of combination with sertraline
in an animal model of depression.
Eur J Pharmacol.
1999;
364
123-132
Reference Ris Wihthout Link
- 110 Hawley C J, Sivakumaran T, Ochocki M. et al .Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors
in twenty-four patients with major depression (abstract). 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) Brussels; 2000
Reference Ris Wihthout Link
- 111
Devarajan S, Dursun S M.
Citalopram plus reboxetine in treatment-resistant depression.
Can J Psychiatry.
2000;
45
489-490
Reference Ris Wihthout Link
- 112
Dursun S M, Devarajan S.
Reboxetine plus citalopram for refractory depression not responding to venlafaxine:
possible mechanisms.
Psychopharmacology.
2001;
153
497-498
Reference Ris Wihthout Link
- 113
Lucca A, Serretti A, Smeraldi E.
Effect of reboxetine augmentation in SSRI resistant patients.
Hum Psychopharmacol.
2000;
15
143-145
Reference Ris Wihthout Link
- 114
Rubio G, San L, Lopez-Munoz F. et al .
Reboxetine adjunct for partial or nonresponders to antidepressant treatment.
J Affect Disord.
2004;
81
67-72
Reference Ris Wihthout Link
- 115
Carpenter L L, Jocic Z, Hall J M. et al .
Mirtazapine augmentation in the treatment of refractory depression.
J Clin Psychiatry.
1999;
60
45-49
Reference Ris Wihthout Link
- 116
Carpenter L L, Yasmin S, Price L H.
A double-blind, placebo-controlled study of antidepresant augmentation with mirtazapine.
Biol Psychiatry.
2002;
51
183-188
Reference Ris Wihthout Link
- 117 Debonnel G, Gobbi G, Turcotte J. et al .The alpha-2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater
antidepressant response: a double-blind controlled study. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology, Dec 10 – 14,. San Juan, Puerto Rico; 2000
Reference Ris Wihthout Link
- 118
Farah A.
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment (letter).
J Clin Psychiatry.
1999;
60
260-261
Reference Ris Wihthout Link
- 119
McGrath P J, Stewart J W, Fava M. et al .
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant
medication trials for depression: a star*D report.
Am J Psychiatry.
2006;
163
1531-1541
Reference Ris Wihthout Link
- 120 Boyer W F, Feighner J P. The combined use of fluoxetine and bupropion (abstract). 146th Annual Meeting of the American Psychiatric Association. San Francisco; 1993
Reference Ris Wihthout Link
- 121
Brodkin J A, Lasser R A, Wines J DJ. et al .
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant
monotherapy.
J Clin Psychiatry.
1997;
58
137-145
Reference Ris Wihthout Link
- 122
Lam R W, Hossie H, Solomons K. et al .
Citalopram and bupropion SR: combining versus switching in patients with treatment-resistant
depression.
J Clin Psychaitry.
2004;
65
337-340
Reference Ris Wihthout Link
- 123
Marshall R D, Randall D, Johannet C M. et al .
Bupropion and sertraline combination treatment in refractory depression.
J Psychopharmacol.
1995;
9
284-286
Reference Ris Wihthout Link
- 124
Spier S A.
Use of bupropion with SSRIs and venlafaxine.
Depress Anxiety.
1998;
7
73-75
Reference Ris Wihthout Link
- 125
Papakostas G I, Worthington J J, Iosifescu D V. et al .
The combination of duloxetine and bupropion for treatment-resistant major depressive
disorder.
Depress Anxiety.
2006;
3
178-181
Reference Ris Wihthout Link
- 126
Young S J.
Panic associated with combining fluoxetine and bupropion (letter).
J Clin Psychiatry.
1996;
57
177-178
Reference Ris Wihthout Link
- 127
Gerner R H, Kaufman K R, Rosen R.
Seizures associated with bupropion and SSRI cotherapy (abstract).
Biol Psychiatry.
1998;
43
995
Reference Ris Wihthout Link
- 128
DeBattista C, Solvason H B, Poirier J. et al .
A prospective trial of bupropion SR augmentation of partial and non-responders to
serotonergic antidepressants.
J Clin Psychopharmacol.
2003;
23
27-30
Reference Ris Wihthout Link
- 129
Clayton A H, McGarvey E L, Abouesh A I. et al .
Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual
dysfunction.
J Clin Psychiatry.
2001;
62
185-190
Reference Ris Wihthout Link
- 130
Kennedy S H, McCann S M, Masellis M. et al .
Combining bupropion SR with venlafaxine, paroxetine or fluoxetine: a preliminary report
on pharmacokinetic, therapeutic, and sexual dysfunction effects.
J Clin Psychiatry.
2000;
63
181-186
Reference Ris Wihthout Link
- 131
Labbate L A, Grimes J B, Hines A. et al .
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
Ann Clin Psychiatry.
1997;
9
241-245
Reference Ris Wihthout Link
- 132
Papakostas G I, Petersen T J, Green C. et al .
A description of next-step switching versus augmentation practices for outpatients
with treatment-resistant major depressive disorder enrolled in an academic speciality
clinic.
Ann Clin Psychiatry.
2005;
3
161-165
Reference Ris Wihthout Link
- 133
Trivedi M H, Fava M, Wisniewski S R. et al .
Medication augmentation after the failure of SSRIs for depression.
N Engl J Med.
2006;
12
1243-1252
Reference Ris Wihthout Link
- 134
Zisook S A, Rush A, Haight B R.
Use of bupropion in combination with serotonin reuptake inhibitors.
Biol Psychiatry.
2006;
59
203-210
Reference Ris Wihthout Link
- 135
Bondolfi G, Chautems C, Rochat B. et al .
Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences
of a fluvoxamine augmentation.
Psychopharmacology.
1996;
128
421-425
Reference Ris Wihthout Link
- 136
Hunchak J.
SSRI combination: treatment for depression (letter).
Can J Psychiatry.
1994;
55
24-25
Reference Ris Wihthout Link
- 137
Coryell W.
Augmentation strategies for inadequate antidepressant response: a review of placebo-controlled
studies.
Ann Clin Psychiatry.
2000;
12
141-146
Reference Ris Wihthout Link
- 138
Bauer M, Linden M.
Die Kombination verschiedener Antidepressiva in der Behandlung therapieresistenter
Depressionen.
Nervenarzt.
1993;
64
343-347
Reference Ris Wihthout Link
- 139
Bauer M, Whybrow P C, Angst J. et al .
WFSBP-Guidelines for biological treatment of unipolar depressive disorders, Part 1:
Acute and continuation treatment of major depressive disorder.
World J Biol Psychiatry.
2002;
3
5-43
Reference Ris Wihthout Link
- 140
Härter M, Sitta P, Keller F. et al .
Stationäre psychiatrisch-psychotherapeutische Depressionsbehandlung. Prozess- und
Ergebnisqualität anhand eines Modellprojekts in Baden-Württemberg.
Nervenarzt.
2004;
75
1083-1091
Reference Ris Wihthout Link
Prof. Dr. Max Schmauß
Bezirkskrankenhaus Augsburg
Dr.-Mack-Str. 1
86156 Augsburg
eMail: m.schmauss@bkh-augsburg.de